Axsome receives ANDA Paragraph IV notice from Apotex for generic Symbravo

Axsome Therapeutics, Inc.

Apotex filed an ANDA seeking FDA approval to market a generic version of Symbravo (meloxicam-rizatriptan benzoate).
Paragraph IV certification notice received August 19, 2025; Axsame plans to respond in due course.
If Axsame sues within 45 days, a 30-month stay could delay generic approval.
Generic competition threatens Symbravo revenue, which is Axsome's key commercial product.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.